Item 1.01 Entry into a Material Definitive Agreement.

Item 1.01 of the Original 8-K is hereby amended and restated as follows:

On September 2, 2022, Yubo International Biotech Limited, a New York Corporation (the "Company") entered into a Securities Purchase Agreement with World Precision Medicine Technology Limited (the "Purchaser"), as further amended by an Amendment to Securities Purchase Agreement, effective as of September 2, 2022, by and between the Company and the Purchaser (as amended, the "Securities Purchase Agreement"), pursuant to which the Company agreed to sell and issue to the Purchaser an aggregate of 1,638,458 shares (the "Shares") of Class A Common Stock, par value $0.001 per share, of the Company, at $0.50 per share, for gross proceeds of $819,229. Such proceeds will be used to settle the entire outstanding principal balances and accrued interest, if any, of all of the loans between the Company, as borrower, and the Purchaser, as lender, in an aggregate amount of $819,229.

This offer and sale of the Shares have been registered under the Securities Act of 1933, as amended, pursuant to the Company's Registration Statement on Form S-1 (Registration No. 333-255805), which was declared effective by the U.S. Securities and Exchange Commission on July 29, 2022.

The foregoing summary of the Securities Purchase Agreement, as amended, does not purport to be complete and is qualified in its entirety by reference to the full terms of the Securities Purchase Agreement and the Amendment to Securities Purchase Agreement, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference into this Item 1.01.




Item 9.01.  Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.                                Description
10.1          Securities Purchase Agreement, dated September 2, 2022, by and between
              the Company and the Purchaser, which was included as Exhibit 10.1 to
              the Original 8-K filed by the Company with the SEC on September 9,
              2022 and is incorporated herein by reference.
  10.2          Amendment to Securities Purchase Agreement, effective as of
              September 2, 2022, by and between the Company and the Purchaser
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)





2

© Edgar Online, source Glimpses